ArticleMedicine2026
A retrospective study of metaplastic breast cancer: Treatment and prognosis through chemotherapy followed by radiotherapy.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metaplastic breast cancer (MBC) is a rare and aggressive form of breast cancer. The effectiveness of chemotherapy followed by radiotherapy (CFRT) for MBC remains controversial. The present study aimed to evaluate the efficacy of CFRT on MBC patients with N0M0. A retrospective study was performed to analyze MBC from the surveillance, epidemiology, and end results database. Breast cancer-specific survival (BCSS) and overall survival (OS) rates were analyzed using the Kaplan-Meier curve. Cox proportional hazard models were used to assess BCSS and OS. CFRT might be a valid therapeutic strategy for MBC with N0M0, especially considered with surgical planning. Of the 4672 MBC patients in the surveillance, epidemiology, and end results registry, our final sample comprised 2260 patients. A total of 602 (26.6%), 292 (12.9%), 638 (28.2%), and 728 (32.2%) patients received non-therapy, only-radiotherapy, only-chemotherapy, and CFRT, respectively. Age, tumor size, tumor grade, surgery, and therapy types were independent indicators for BCSS. The Kaplan-Meier analysis showed that total mastectomy (TM) not breast-conserving surgery (BCS) improved BCSS of MBC receiving CFRT, whereas OS of MBC receving CFRT can not benefit from surgical type. Further exploration illustrated that, for BCSS, only stage T2 and T3 MBC patients underwent BCS and only stage T3 MBC patients underwent TM could benefit from CFRT. However, for OS, all stage MBC patients underwent BCS and only stage T3 MBC patients underwent TM could benefit from CFRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.